Bausch Health Companies Inc.
NYSE:BHC · New York Stock Exchange
-$0.11 today
Vol 3.71M · Avg 1.70M
Management
Put operating results in leadership context
Review returns on capital, executive background, insider transactions, and growth quality to judge whether management is compounding value well.
Return Metrics
ROE, ROIC & ROA over time
ROE
-28.9%
avg 45.1%
ROIC
3.2%
avg 0.1%
ROA
0.6%
avg -2.5%
Analysis
ROIC is currently the strongest return metric at 3.2% versus its period average of 0.1%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Tenure | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|---|
Thomas J. Appio | Chief Executive Officer & Director | $3.84M | — | 64 | $3.45M | 0.92% |
Jean-Jacques Charhon | Executive Vice President & Chief Financial Officer | $1.39M | — | 61 | $706,478.00 | 0.19% |
Seana Carson | Executive Vice President & General Counsel | $1.33M | — | 53 | $616,761.00 | 0.17% |
Aimee J. Lenar | Executive Vice President of US Pharma | $1.31M | — | 50 | $400,335.00 | 0.11% |
Jonathan Sadeh | Executive Vice President, Chief Medical Officer and Head of R&D | — | — | — | — | — |
Cees Heiman | Senior Vice President of Europe & Canada | — | — | — | — | — |
Garen Sarafian | Vice President & Head of Investor Relations | — | — | — | — | — |
Jiny Kim | Senior Vice President of Solta Medical | — | — | 48 | — | — |
Kathleen Fitzpatrick | Executive Vice President and Chief HR & Communications Officer | — | — | — | — | — |
Mirza Dautbegovic | Executive Vice President & Chief Operating Officer | — | — | — | — | — |
Steven Lee | Senior Vice President, Controller & Chief Accounting Officer | — | — | 55 | $95,210.00 | 0.03% |
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
5
$349.38M
Sells
6
$467,456.38
Net Sentiment
+$348.92M
Net buying
Most Active
Carson Seana
4 transactions
1–10 of 11
Analysis
Insiders reported 5 buys worth $349.38M and 6 sells worth $467,456.38 over the last 12 months. That adds up to net buying of $348.92M. Carson Seana was the most active insider with 4 transactions.
Growth Analysis
Historical CAGR & forward analyst estimates
| Metric | 10yr | 5yr | 3yr | Fwd Est. |
|---|---|---|---|---|
| EPS | N/A | N/A | N/A | N/A1 analysts |
| Revenue | N/A | N/A | +44.2% | -0.7% (15yr)1 analysts |
| Net Income | N/A | N/A | N/A | N/A1 analysts |
| EBIT | N/A | N/A | +167.6% | +1.1% (15yr)1 analysts |
Analysis
Recent growth has been strongest in EBIT at +167.6% over three years. Forward estimates point to EBIT at +1.1% (15yr), giving you a quick check on whether expectations are accelerating or cooling.
Competitors
Peer companies in the same sector
Catalyst Pharmaceuticals, Inc.
NASDAQ:CPRX
$3.84B
Concentra Group Holdings Parent, Inc.
NYSE:CON
$3.65B
Beam Therapeutics Inc.
NASDAQ:BEAM
$3.39B
Haemonetics Corporation
NYSE:HAE
$3.34B
DENTSPLY SIRONA Inc.
NASDAQ:XRAY
$2.06B
ANI Pharmaceuticals, Inc.
NASDAQ:ANIP
$1.79B
HUTCHMED (China) Limited
NASDAQ:HCM
$1.79B
Mineralys Therapeutics, Inc.
NASDAQ:MLYS
$1.69B
Perrigo Company plc
NYSE:PRGO
$1.37B
Alvotech
NASDAQ:ALVO
$1.22B
Who manages BHC?
Bausch Health Companies Inc. (BHC) lists 11 active executives. The top listed executive is Jonathan Sadeh, Executive Vice President, Chief Medical Officer and Head of R&D.
Are BHC insiders buying or selling?
Recent insider activity shows net buying of $371.58M.
Explore More
Continue the stock analysis
Jump to another research area for this company.